SUNNYVALE, Calif.--Gene-based therapeutics developer, Hyseq here announced four recent additions to its management team: Robert D'Elia, formerly an operations executive with Turner Construction and Eichleay Architects and Engineers, joined Hyseq as senior director of facilities operations; Stephanie Diaz, formerly of Martek Biosciences, joined as director of finance; Andrew Kumamoto came from the law firm McCutchen, Doyle, Brown and Enersen to be Hyseq's director of intellectual property; and Nandini Tandon joined the company as director of corporate development from Chiron where she was commercial development manager.
Hyseq applies the proprietary DNA array technology of its integrated HyX genomics platform to produce gene-based therapeutic product candidates. The company claims that its proprietary HyGenomics database of partial human gene sequences is the world's largest.